Harmony Biosciences (HRMY) Tops Q2 EPS by 15c
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 9/21/2026
- S&P 500, Nasdaq advance, turning the page on a tumultuous week
- Oil slides after China asks Iran to limit Houthi attacks on Saudi oil facilities
- Warren Buffett transitions to Berkshire’s chairman emeritus
- Is the S&P 500 in an "earnings bubble"? Goldman weighs in
- Wells Fargo cuts Netflix rating on engagement risk, weak slate
- Far-left party wins Berlin election, pledging to nationalise housing
- Cybercrime feud erupts on dark web as notorious group claims hijack of rival's website
- S&P 500, Nasdaq advance, turning the page on a tumultuous week
- Anthropic and Accenture partner on embedded AI safety evaluation
- Wells Fargo cuts Netflix rating on engagement risk, weak slate
Harmony Biosciences Reports Second Quarter 2023 Financial Results and Business Updates
August 1, 2023 7:30 AM EDTWAKIX® (pitolisant) Net Revenue Increased ~25% Year-over-Year to $134.2 Million for Second Quarter 2023
Average Number of Patients on WAKIX Increased by ~350 Sequentially to ~5,450 for Second Quarter 2023
Exited Second Quarter 2023 With ~5,600 Patients on WAKIX
Completed Enrollment in Phase 3 Idiopathic Hypersomnia (IH) INTUNE Study; On-track for Topline Data in Fourth Quarter 2023
Plans to Initiate Prader-Willi Syndrome (PWS) Phase 3 Study in Fourth Quarter 2023
Board of Directors Authorized $125 Million Share Repurchase Program
Conference Call... More
